# Benefits and Harms Assessment Framework for RCTs

## Overview

Comprehensive benefit-harm assessment evaluates both therapeutic benefits (efficacy) and adverse effects (harms) to inform clinical decision-making. This framework provides systematic criteria for assessing benefit-harm balance in RCTs.

**Purpose**: Evaluate therapeutic benefits, adverse events, and risk-benefit balance
**Items**: 15 items across 3 domains (Benefits: 5 items, Harms: 7 items, Balance: 3 items)
**Rating Scale**: ✓ (adequate), ⚠ (concerns), ✗ (inadequate), N/A (not applicable)
**Principle**: Never evaluate benefits without evaluating harms

## Why Benefits AND Harms Matter

**Historical failures:**
- Rofecoxib (Vioxx): Cardiovascular harms outweighed gastrointestinal benefits
- Thalidomide: Teratogenic effects overshadowed anti-nausea benefits
- Rosiglitazone (Avandia): Cardiovascular mortality risk negated glycemic benefits

**Modern imperative:**
- FDA and EMA require comprehensive safety reporting
- Patient-centered care demands informed decision-making
- Value assessments (QALY, ICER) require benefit-harm data
- Clinical guidelines integrate benefit-harm balance

**Key principle**: An intervention with significant benefits but catastrophic rare harms may have unfavorable risk-benefit profile

## Domain A: Benefits Assessment (5 items)

### Item B1: Efficacy Evidence

**Criterion**: Does the trial demonstrate statistically significant improvement in primary outcome?

**Assessment:**
- Effect size magnitude and direction
- Statistical significance (p<0.05 and confidence interval excludes null)
- Consistency across sensitivity analyses
- Robustness to missing data assumptions

**Rating Guidance:**
- ✓: Statistically significant benefit with adequate power and robust analyses
- ⚠: Borderline significance, or significant but fragile to assumptions
- ✗: No statistically significant benefit, or benefit only in post-hoc analyses
- N/A: Rarely applicable for efficacy trials

**Evidence to document:**
- Primary outcome result with 95% CI
- P-value and statistical test used
- Sensitivity analyses results
- Missing data impact

### Item B2: Clinical Significance

**Criterion**: Is the magnitude of benefit clinically meaningful to patients?

**Assessment:**
- Minimal clinically important difference (MCID) exceeded
- Patient-important outcomes improved (not just surrogate markers)
- Effect size sufficient to change clinical practice
- Number needed to treat (NNT) is acceptable

**Rating Guidance:**
- ✓: Effect exceeds MCID; NNT <20 for patient-important outcome
- ⚠: Statistically significant but clinically marginal (e.g., NNT 50-100)
- ✗: Effect below MCID; only surrogate outcomes improved
- N/A: MCID not established for outcome

**Clinical Significance Benchmarks:**

| Outcome Type | Clinically Meaningful Effect |
|--------------|----------------------------|
| Mortality | NNT <50 for 1-year mortality; RRR >20% |
| Cardiovascular events | NNT <30 for major events (MI, stroke) |
| Pain (VAS 0-100) | Reduction ≥15 points (MCID) |
| Quality of life (SF-36) | Improvement ≥5 points (MCID) |
| Function (walking distance) | Improvement ≥50 meters |
| Symptoms (depression, anxiety) | Effect size d ≥0.5 (moderate) |

**Evidence to document:**
- Effect size in clinical units
- Comparison to MCID from literature
- NNT calculation
- Patient perspective on meaningfulness

### Item B3: Consistency of Benefit

**Criterion**: Is benefit consistent across subgroups and outcomes?

**Assessment:**
- Primary and secondary outcomes show concordant effects
- Key patient subgroups benefit (age, sex, severity)
- No substantial subgroup heterogeneity without explanation
- Sensitivity analyses confirm main findings

**Rating Guidance:**
- ✓: Consistent benefit across outcomes and subgroups
- ⚠: Benefit limited to specific subgroups or some outcomes
- ✗: Inconsistent findings; benefit only in selected analyses
- N/A: Insufficient subgroup data

**Evidence to document:**
- Secondary outcome results
- Subgroup analysis results (pre-specified)
- Heterogeneity assessment
- Consistency statement

### Item B4: Durability of Benefit

**Criterion**: Is benefit sustained over clinically relevant time period?

**Assessment:**
- Follow-up duration adequate for outcome (e.g., ≥1 year for chronic disease)
- Benefit maintained at end of follow-up (not just immediate post-treatment)
- No evidence of tachyphylaxis or tolerance
- Long-term sustainability addressed

**Rating Guidance:**
- ✓: Adequate follow-up with sustained benefit
- ⚠: Short follow-up or benefit attenuates over time
- ✗: Benefit only immediate post-treatment; long-term outcomes not assessed
- N/A: Acute condition where long-term follow-up not needed

**Follow-Up Duration Benchmarks:**

| Condition Type | Adequate Follow-Up |
|----------------|-------------------|
| Chronic disease management | ≥12 months |
| Cancer treatment | ≥5 years (or disease-specific) |
| Cardiovascular prevention | ≥2 years |
| Mental health intervention | ≥6 months post-treatment |
| Acute condition | Variable; 30-90 days often sufficient |

**Evidence to document:**
- Follow-up duration
- Time course of effect (immediate, sustained, delayed)
- Attrition rate at final follow-up
- Statement on durability

### Item B5: Benefit Reporting Quality

**Criterion**: Are benefits reported completely and transparently?

**Assessment:**
- All pre-specified outcomes reported
- Effect sizes with confidence intervals (not just p-values)
- Absolute AND relative measures reported
- Responder analysis included (proportion achieving clinically meaningful improvement)

**Rating Guidance:**
- ✓: Complete reporting with effect sizes, CIs, and multiple metrics
- ⚠: Incomplete reporting (e.g., only RR without absolute risk difference)
- ✗: Selective outcome reporting or p-values without effect sizes
- N/A: Rarely applicable

**Evidence to document:**
- Comparison of registered vs reported outcomes
- Presence of effect sizes + 95% CI
- Absolute risk difference or NNT reported
- Responder analysis (if applicable)

## Domain H: Harms Assessment (7 items)

### Item H1: Adverse Events Completeness

**Criterion**: Are adverse events systematically and comprehensively collected and reported?

**Assessment:**
- Systematic AE collection method described
- All adverse events reported (not just "related" or "serious")
- Both groups compared (not just intervention group)
- Numerical data provided (not just "no significant difference")

**Rating Guidance:**
- ✓: Systematic AE collection with complete reporting for both groups
- ⚠: Some AE data but incomplete (e.g., only serious AEs, or only intervention group)
- ✗: Minimal or no AE reporting; statement like "well-tolerated" without data
- N/A: Not applicable for non-therapeutic interventions

**Minimum Reporting Standards:**
- Number of patients with ≥1 AE in each group
- Number of serious adverse events (SAEs) in each group
- Specific common AEs with frequencies
- Deaths in each group with causes
- Withdrawals due to AEs

**Evidence to document:**
- AE collection method (solicited, spontaneous, standardized checklist)
- Total AE count by group
- SAE count by group
- AE table present

### Item H2: Severity Assessment

**Criterion**: Are adverse events graded by severity?

**Assessment:**
- Severity grading system used (e.g., CTCAE, MedDRA)
- Distribution of AE severity reported (mild, moderate, severe, life-threatening)
- Serious adverse events (SAEs) clearly distinguished
- Dose modifications or discontinuations due to AEs reported

**Rating Guidance:**
- ✓: Standardized severity grading with distribution reported
- ⚠: Some severity information but not systematically graded
- ✗: No severity grading; all AEs lumped together
- N/A: If no AEs occurred (rare and should be explicitly stated)

**Common Severity Scales:**
- **CTCAE** (Common Terminology Criteria for Adverse Events): Grade 1-5
- **MedDRA** (Medical Dictionary for Regulatory Activities): Severity classification
- **ICH Guidelines**: Mild/Moderate/Severe classification

**Evidence to document:**
- Severity grading system used
- Distribution of AE grades
- SAE definition and count
- Dose modifications due to AEs

### Item H3: Causality Assessment

**Criterion**: Is the relationship between intervention and adverse events assessed?

**Assessment:**
- Causality assessment method described
- AEs categorized by relationship to intervention (related, possibly related, unrelated)
- Investigators evaluate whether AE is intervention-related
- Temporal relationship considered

**Rating Guidance:**
- ✓: Systematic causality assessment with categorization reported
- ⚠: Some causality assessment but not systematic or not reported
- ✗: No causality assessment; assumes all AEs are intervention-related or ignores relationship
- N/A: For comparison of active interventions where all AEs are relevant

**Causality Categories:**
- **Definitely related**: Certain relationship (rechallenge positive, no other explanation)
- **Probably related**: Likely relationship (temporal, known AE, resolved on discontinuation)
- **Possibly related**: Uncertain relationship (temporal but other causes possible)
- **Unlikely related**: Probably not related (alternative explanation likely)
- **Not related**: Definitely not related (no temporal relationship, clear alternative cause)

**Evidence to document:**
- Causality assessment method
- Distribution of AEs by relatedness
- Investigator judgment process
- Treatment-emergent AEs vs pre-existing conditions

### Item H4: Specific Harms of Interest

**Criterion**: Are pre-specified or known harms of interest systematically assessed?

**Assessment:**
- Pre-specified safety outcomes defined and assessed
- Known class effects or mechanism-based harms monitored
- Standardized assessments for harms of interest (not just spontaneous reporting)
- Negative findings reported (e.g., "no cases of hepatotoxicity observed")

**Rating Guidance:**
- ✓: Pre-specified harms systematically assessed with standardized measures
- ⚠: Some harms of interest mentioned but not systematically assessed
- ✗: Only spontaneous AE reporting; no targeted harm assessment
- N/A: If no specific harms of concern for intervention class

**Examples of Specific Harms:**
- **Cardiovascular drugs**: MI, stroke, arrhythmias (ECG monitoring)
- **Psychiatric drugs**: Suicidality (C-SSRS scale), akathisia, weight gain
- **NSAIDs**: GI bleeding (endoscopy if symptomatic), cardiovascular events
- **Immunosuppressants**: Infections (viral load, cultures), malignancies
- **Anticoagulants**: Bleeding events (standardized bleeding scale like ISTH or BARC)

**Evidence to document:**
- Pre-specified safety outcomes in protocol/registration
- Standardized harm assessment tools used
- Monitoring frequency and methods
- Results for each harm of interest

### Item H5: Withdrawals and Discontinuations

**Criterion**: Are withdrawals due to adverse events reported with reasons?

**Assessment:**
- Number and proportion of withdrawals due to AEs in each group
- Specific reasons for AE-related withdrawals
- Differential withdrawal rates between groups assessed
- Impact of AE-related withdrawals on adherence and ITT analysis

**Rating Guidance:**
- ✓: AE-related withdrawals reported by group with specific reasons
- ⚠: Withdrawal numbers reported but reasons not specified
- ✗: Withdrawals not distinguished from loss to follow-up; no AE attribution
- N/A: If no withdrawals occurred

**Key Metrics:**
- Total withdrawals by group
- Withdrawals due to AEs by group (%)
- Withdrawals due to lack of efficacy by group (%)
- Most common AEs leading to withdrawal
- Time to withdrawal

**RED FLAGS:**
- Differential withdrawal rates (e.g., 20% intervention vs 5% control)
- High withdrawal rate (>20%) suggests tolerability issues
- Withdrawals due to serious AEs (indicates safety concerns)

**Evidence to document:**
- CONSORT flow diagram showing AE withdrawals
- Table of reasons for withdrawal
- Statistical comparison of withdrawal rates
- Sensitivity analysis including withdrawn patients

### Item H6: Death and Serious Adverse Events

**Criterion**: Are deaths and SAEs comprehensively reported?

**Assessment:**
- All deaths reported by group with causes
- Serious adverse events defined and reported
- Relationship of deaths/SAEs to intervention assessed
- Temporal relationship to intervention documented

**Rating Guidance:**
- ✓: All deaths and SAEs reported with causes and relationship assessment
- ⚠: Deaths/SAEs reported but causes or relationship not fully described
- ✗: Deaths/SAEs not reported or minimized
- N/A: If no deaths or SAEs (must be explicitly stated)

**Serious Adverse Event Definition (ICH-GCP):**
SAE is any adverse event that:
- Results in death
- Is life-threatening
- Requires hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect
- Is medically significant (requires intervention to prevent one of above)

**Evidence to document:**
- Death count by group with causes
- SAE count by group with types
- Causality assessment for deaths/SAEs
- Timeline of deaths/SAEs relative to treatment

### Item H7: Harms Reporting Transparency

**Criterion**: Are harms reported with equal rigor and transparency as benefits?

**Assessment:**
- Harms presented in Results section (not buried in Discussion)
- Tables/figures for major harms (not just text)
- Numerical data for harms (not vague statements like "few adverse events")
- Balance of space devoted to harms vs benefits in Discussion

**Rating Guidance:**
- ✓: Harms reported with detailed tables, numerical data, and balanced discussion
- ⚠: Harms mentioned but less prominently than benefits
- ✗: Harms minimized, vague, or relegated to supplementary materials
- N/A: Rarely applicable

**Indicators of Poor Harms Reporting:**
- "No serious adverse events reported" (did none occur or were they not collected?)
- "Well-tolerated" without data
- "No significant difference in AEs" without frequencies
- AE table in supplementary materials only
- Harms discussed only when questioned by reviewers

**Evidence to document:**
- Presence of AE table in main text
- Numerical AE data (not just p-values)
- Discussion of harms in relation to benefits
- Acknowledgment of harms limitations

## Domain R: Risk-Benefit Balance (3 items)

### Item R1: Benefit-Harm Trade-Off

**Criterion**: Do benefits outweigh harms for typical patient?

**Assessment:**
- NNT vs NNH comparison
- Severity of benefit vs severity of harm
- Frequency of benefit vs frequency of harm
- Reversibility of harms

**Rating Guidance:**
- ✓: Benefits clearly outweigh harms (NNT < NNH; serious benefit > minor harms)
- ⚠: Uncertain balance; trade-offs depend on patient values
- ✗: Harms outweigh benefits (NNT > NNH; minor benefit < serious harms)
- N/A: Cannot assess without complete benefit and harm data

**Benefit-Harm Balance Framework:**

| Scenario | NNT | NNH | Severity Balance | Risk-Benefit |
|----------|-----|-----|------------------|--------------|
| Favorable | 5 | 100 | Major benefit, minor harms | ✓ Positive |
| Uncertain | 20 | 30 | Moderate benefit, moderate harms | ⚠ Depends on patient values |
| Unfavorable | 50 | 15 | Minor benefit, serious harms | ✗ Negative |

**Additional Considerations:**
- **Time course**: Immediate harms vs delayed benefits?
- **Reversibility**: Permanent harms vs transient benefits?
- **Individual variation**: Predictable responders vs non-responders?

**Evidence to document:**
- NNT and NNH calculations
- Comparative severity of benefits vs harms
- Patient perspective on trade-offs
- Subgroups with favorable vs unfavorable balance

### Item R2: Patient-Important Outcomes

**Criterion**: Are patient-important outcomes prioritized over surrogate markers?

**Assessment:**
- Benefits and harms assessed for outcomes patients care about (symptoms, function, quality of life, mortality)
- NOT just surrogate outcomes (lab values, imaging findings)
- Patient-reported outcomes included
- Benefit-harm balance considers patient priorities

**Rating Guidance:**
- ✓: Patient-important outcomes are primary; surrogate markers secondary
- ⚠: Mix of patient-important and surrogate outcomes
- ✗: Only surrogate outcomes; no patient-important outcomes
- N/A: Early-phase trial where surrogate markers appropriate

**Patient-Important vs Surrogate Outcomes:**

| Surrogate Outcome | Patient-Important Outcome |
|-------------------|---------------------------|
| HbA1c level | Diabetic complications, hypoglycemia, quality of life |
| Blood pressure | Stroke, MI, heart failure |
| LDL cholesterol | Cardiovascular death, MI |
| Bone mineral density | Fractures, pain, mobility |
| Tumor size | Survival, quality of life, symptoms |
| FEV1 | Exacerbations, dyspnea, exercise tolerance |

**Evidence to document:**
- Primary outcomes: patient-important vs surrogate
- Patient-reported outcome measures used
- Patient involvement in outcome selection
- Discussion of surrogate-to-clinical outcome relationship

### Item R3: Subgroup Considerations

**Criterion**: Is benefit-harm balance assessed across key patient subgroups?

**Assessment:**
- Subgroup analyses for age, sex, disease severity
- Identification of subgroups with particularly favorable or unfavorable balance
- Consideration of comorbidities affecting risk
- Personalized risk-benefit assessment discussed

**Rating Guidance:**
- ✓: Subgroup-specific benefit-harm balance discussed
- ⚠: Subgroup analyses conducted but balance not explicitly assessed
- ✗: No subgroup assessment; assumes uniform benefit-harm balance
- N/A: Small sample size precludes meaningful subgroup analysis

**Key Subgroups for Risk-Benefit:**
- **Age**: Elderly may have different risk tolerance
- **Severity**: Mild disease may not justify risks; severe disease may
- **Comorbidities**: Polypharmacy increases AE risk
- **Frailty**: Frail patients at higher risk for harms
- **Contraindications**: Absolute vs relative contraindications

**Examples:**
- Anticoagulation: Favorable for high stroke risk / low bleeding risk; unfavorable for opposite
- Chemotherapy: Favorable for fit patients with good prognosis; unfavorable for frail/poor prognosis
- Surgery: Favorable for young/healthy; unfavorable for elderly with comorbidities

**Evidence to document:**
- Subgroup analyses conducted
- Interaction tests for benefit and harm
- Discussion of which patients likely to benefit
- Risk stratification tools applied

## Overall Benefit-Harm Assessment Summary

### Comprehensive Assessment

**Rate overall adequacy of benefit-harm assessment:**

| Domain | Items | Adequate (✓) | Concerns (⚠) | Inadequate (✗) | N/A |
|--------|-------|--------------|--------------|----------------|-----|
| Benefits | 5 | ___ | ___ | ___ | ___ |
| Harms | 7 | ___ | ___ | ___ | ___ |
| Balance | 3 | ___ | ___ | ___ | ___ |
| **TOTAL** | **15** | **___** | **___** | **___** | **___** |

**Overall Completeness:**
- **Comprehensive**: ≥12/15 items adequate (80%)
- **Adequate**: 9-11/15 items adequate (60-73%)
- **Incomplete**: 6-8/15 items adequate (40-53%)
- **Inadequate**: <6/15 items adequate (<40%)

### Risk-Benefit Conclusion

Synthesize overall assessment:

**Favorable Benefit-Risk Profile:**
- Clinically significant benefits (NNT <10)
- Rare or minor harms (NNH >100)
- Patient-important outcomes improved
- Benefits clearly outweigh harms for typical patient

**Uncertain Benefit-Risk Profile:**
- Modest benefits (NNT 10-50)
- Moderate harms (NNH 20-100)
- Trade-offs require patient preference elicitation
- Balance depends on individual risk factors and values

**Unfavorable Benefit-Risk Profile:**
- Small or non-significant benefits (NNT >50)
- Frequent or serious harms (NNH <20)
- Surrogate outcomes only
- Harms outweigh benefits for typical patient

## Common Benefit-Harm Reporting Failures

1. **Selective emphasis**: Benefits highlighted; harms minimized
2. **Incomplete AE reporting**: "No serious adverse events" without complete data
3. **Statistical misdirection**: "No significant difference in AEs" when actual rates differ meaningfully
4. **Surrogate focus**: Biomarker improvement without patient-important outcomes
5. **Lack of balance**: Pages on benefits, one paragraph on harms
6. **Missing NNH**: NNT reported but NNH not calculated
7. **Subgroup failure**: Overall benefit-harm without subgroup assessment

## References

1. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. *PLoS Med* 2016;13(9):e1002127.

2. Ioannidis JP, Evans SJ, Gøtzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004;141(10):781-8.

3. Chou R, Aronson N, Atkins D, et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. *J Clin Epidemiol* 2010;63(5):502-12.

4. Levine MAH, Shiff NJ, Stelfox HT. Quality of safety reporting in randomized controlled trials: a systematic review. *J Clin Epidemiol* 2017;83:56-64.

5. Phillips R, Sauzet O, Cornelius V. Statistical methods for the analysis of adverse event data in randomised controlled trials: a scoping review and taxonomy. *BMC Med Res Methodol* 2020;20:288.
